产品参数
品 名 货 号 CAS 号 纯 度 规 格 价格 Pertuzumab PHM220224 205923-56-4 ≥99.10% 1 mg ¥2900 5 mg ¥5700 25mg ¥21650 5 0mg ¥34500 产品简介
品 名
货 号
CAS 号
纯 度
规 格
价格
Pertuzumab
PHM220224
205923-56-4
≥99.10%
1 mg
¥2900
5 mg
¥5700
25mg
¥21650
5 0mg
¥34500
Pertuzumab 是一种人源化单克隆抗体,是一种HER2二聚抑制剂。可用于转移性HER2 阳性乳腺癌的研究。
详细介绍
生物活性 Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer. IC50 & Target HER2 体外研究 (In Vitro) Trastuzumab and Pertuzumab are highly synergistic inhibitors of BT474 breast cancer cell survival. The combination of trastuzumab and Pertuzumab mediates a loss of up to 60% of cells at doses in which individual drugs do not alter cell survival. The combination of trastuzumab and Pertuzumab reduces the percentage of proliferating (S-phase) cells by more than 2-fold. A combination of trastuzumab and Pertuzumab inhibits cell proliferation and survival to a greater degree than does either agent alone. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 体内研究 (In Vivo) In Calu-3 NSCLC xenografts, monotherapy with pertuzumab or trastuzumab is able to significantly inhibit tumor growth, with treatment-to-control ratios (TCR) of 0.23 and 0.27 respectively. The combination of trastuzumab and pertuzumab produces a dramatically enhanced antitumor activity compared with single-agent treatments (TCR 0.05, resulting in tumor regression and, in 3 of 10 animals, complete tumor remission). Treatment of KPL-4 breast cancer xenografts with either trastuzumab or pertuzumab inhibits tumor growth with TCRs of 0.67 and 0.65, respectively. Pertuzumab maintains antitumor activity after progression on trastuzumab. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 分子量 145175.18 CAS 号 380610-27-5 中文名称 帕妥株单抗 储存方式 Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the
treatment of metastatic HER2-positive breast cancer.
IC50 & Target HER2
体外研究 (In Vitro)
Trastuzumab and Pertuzumab are highly synergistic inhibitors of BT474 breast cancer cell
survival. The combination of trastuzumab and Pertuzumab mediates a loss of up to 60%
of cells at doses in which individual drugs do not alter cell survival. The combination of
trastuzumab and Pertuzumab reduces the percentage of proliferating (S-phase) cells
by more than 2-fold. A combination of trastuzumab and Pertuzumab inhibits cell
proliferation and survival to a greater degree than does either agent alone.
MCE has not independently confirmed the accuracy of these methods. They are for
reference only.
体内研究 (In Vivo)
In Calu-3 NSCLC xenografts, monotherapy with pertuzumab or trastuzumab is able to
significantly inhibit tumor growth, with treatment-to-control ratios (TCR) of 0.23 and 0.27
respectively. The combination of trastuzumab and pertuzumab produces a dramatically
enhanced antitumor activity compared with single-agent treatments (TCR 0.05, resulting
in tumor regression and, in 3 of 10 animals, complete tumor remission). Treatment of
KPL-4 breast cancer xenografts with either trastuzumab or pertuzumab inhibits tumor
growth with TCRs of 0.67 and 0.65, respectively. Pertuzumab maintains antitumor activity
after progression on trastuzumab.
分子量
145175.18
380610-27-5
中文名称
帕妥株单抗
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
销售电话:4006-169-114 技术咨询:020-32290876 客服电话:020-84224925 Email:whiga22@126.com 生产地址:广州国际生物岛螺旋四路1号研发A区第三层302房
粤公网安备 44011202000535号